Improvement of 11 patients with nail psoriasis with apremilast: Results of an investigator-initiated open-label study

ObjectiveNail psoriasis is common, impairs fine motor finger functioning, affects cosmesis, and is associated with a lower quality of life. This review updates the previous Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for nail psoriasis.MethodsThis systematic literature review of the PubMed, MEDLINE, Embase, and Cochrane databases examined the updated evidence since the last GRAPPA nail psoriasis treatment recommendations published in 2014. Recommendations are based on preformed PICO (Patient/Population - Intervention - Comparison/Comparator - Outcome) questions formulated by an international group of dermatologists, rheumatologists, and patient panel members. Data from this literature review were evaluated in line with Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology.ResultsOverall, there is insufficient evidence to make any recommendation for the use of topical corticosteroids, topical calcipotriol, topical tazarotene, topical cyclosporine, dimethyl fumarates/fumaric acid esters, phototherapy, and alitretinoin. There is a low strength of evidence to support the use of calcipotriol and corticosteroid preparations, topical tacrolimus, oral cyclosporine, oral methotrexate, intralesional corticosteroids, pulsed dye laser, acitretin, Janus kinase inhibitors, and apremilast.ConclusionThe highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.

show abstract

“…In patients with nail psoriasis, there is a conditional strength recommendation (*) for the use of apremilast. [47][48][49][50][51][52][53][54]…”

Section: Resultsmentioning

confidence: 99%

Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

et al. 2022

View full text Add to dashboard Cite

show abstract

“…3 Oral apremilast is a useful therapeutic strategy in nail psoriasis, and improvement was seen as early as week 12 when apremilast was administrated. 4 Less commonly, however, unusually successful improvement of severe nail psoriasis achieved with apremilast has been reported. 2 What distinguishes the current from previous cases is significant improvement in NAPSI even after the discontinuation.…”

Section: Long-term Remission Of Severe Nail Psoriasis After Discontinuation Of Apremilast In a Colorectal Cancer Survivormentioning

confidence: 99%

Long‐term remission of severe nail psoriasis after discontinuation of apremilast in a colorectal cancer survivor

Kurata

Ohyama

2021

The Journal of Dermatology

View full text Add to dashboard Cite

Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review

2023

View full text Add to dashboard Cite

Improvement of 11 patients with nail psoriasis with apremilast: Results of an investigator-initiated open-label study

Cited by 6 publications

References 5 publications

Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

Long‐term remission of severe nail psoriasis after discontinuation of apremilast in a colorectal cancer survivor

Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review

Contact Info

Product

Resources

About